# OnCo record gist-imatinib-resistant (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/gist-imatinib-resistant/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "gist-imatinib-resistant" ;
  schema:name "Imatinib-resistant GIST"@en ;
  schema:alternateName "Imatinib-refractory GIST"@en, "GIST with secondary KIT mutations"@en, "Advanced GIST after imatinib"@en, "Multidrug-resistant GIST"@en ;
  schema:description "Imatinib-resistant GIST is disease that has grown through the first drug, usually because the tumour has acquired a second KIT mutation that imatinib cannot block. Sunitinib, regorafenib and ripretinib are given in turn; ripretinib, in the INVICTUS trial, extended progression-free survival from 1 to 6 months in patients who had exhausted the other three."@en ;
  schema:url <https://onco.cc/cancers/gist-imatinib-resistant/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ripretinib> ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/32511981/>, <https://pubmed.ncbi.nlm.nih.gov/35947817/>, <https://en.wikipedia.org/wiki/Ripretinib> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/trials/insight-gist/>, <https://onco.cc/drugs/idrx-42/>, <https://onco.cc/drugs/nb003/>, <https://onco.cc/drugs/bezuclastinib/>, <https://onco.cc/drugs/ripretinib/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:standardOfCare <https://onco.cc/drugs/imatinib/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/targets/kit/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/ripretinib/>, <https://onco.cc/trials/nct03673501/>, <https://onco.cc/trials/insight-gist/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/ripretinib/>, <https://onco.cc/trials/invictus/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/idrx-42/>, <https://onco.cc/drugs/nb003/>, <https://onco.cc/drugs/bezuclastinib/> .